Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure

Abstract

The article presents the results of a 6-month long-term therapy with angiotensin II receptor blocker Valsacor and aldosterone receptor blocker Spironolactone in patients with chronic heart failure (CHF) against a background of ischemic and/or post-infarction left ventricular remodelling. The results show that the renin-angiotensin-aldosterone system (RAAS) blockade in the combination therapy slows down the pathological remodelling of the left ventricle (LV) and thus prevents progression of CHF in a majority of patients with myocardial infarction (MI).

Keywords

• блокатор рецепторов ангиотензина
• блокатор рецепторов альдостерона
• ремоделирование лж
• сердечная недостаточность
• дисфункция миокарда
• angiotensin receptor blocker
• aldosterone receptor blocker
• lv remodeling
• heart failure
• myocardial dysfunction